Ilan Daskal Net Worth

The estimated Net Worth of Ilan Daskal is at least $354 Thousand dollars as of 11 June 2021. Mr. Daskal owns over 2,500 units of Natus Medical Inc stock worth over $285,038 and over the last 10 years he sold NTUS stock worth over $68,650. In addition, he makes $0 as Independent Director at Natus Medical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Daskal NTUS stock SEC Form 4 insiders trading

Ilan has made over 3 trades of the Natus Medical Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of NTUS stock worth $68,650 on 11 June 2021.

The largest trade he's ever made was exercising 8,333 units of Natus Medical Inc stock on 21 June 2014 worth over $274,656. On average, Ilan trades about 1,621 units every 232 days since 2014. As of 11 June 2021 he still owns at least 8,648 units of Natus Medical Inc stock.

You can see the complete history of Mr. Daskal stock trades at the bottom of the page.

Ilan Daskal biography

Ilan Daskal serves as Independent Director of the Company. He holds the position of Executive Vice President and Chief Financial Officer of Bio-Rad Laboratories, Inc. Over his career Mr. Daskal has held numerous senior financial roles and CFO positions at both public and private companies that include Lumileds, International Rectifier Corporation and Infineon. Mr. Daskal also served on the Board of Directors of Ixia. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.

How old is Ilan Daskal?

Ilan Daskal is 54, he's been the Independent Director of Natus Medical Inc since 2020. There are 12 older and 2 younger executives at Natus Medical Inc. The oldest executive at Natus Medical Inc is Kenneth Ludlum, 66, who is the Independent Director.

What's Ilan Daskal's mailing address?

Ilan's mailing address filed with the SEC is C/O VIAVI SOLUTIONS INC., 1445 SOUTH SPECTRUM BLVD, SUITE 102, CHANDLER, AZ, 85286.

Insiders trading at Natus Medical Inc

Over the last 5 years, insiders at Natus Medical Inc have traded over $3,793,396 worth of Natus Medical Inc stock. The most active insiders traders include Dong Chune Christopher Chung, Joshua Levine, and Jonathan Kennedy. On average, Natus Medical Inc executives and independent directors trade stock every 70 days with the average trade being worth of $543,972. The most recent stock trade was executed by Dong Chune Christopher Chung on 9 December 2021, trading 11,787 units of NTUS stock currently worth $243,755.

What does Natus Medical Inc do?

Natus Medical Incorporated is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.

Complete history of Mr. Daskal stock trades at Viavi Solutions Inc and Natus Medical Inc

Natus Medical Inc executives and stock owners

Natus Medical Inc executives and other stock owners filed with the SEC include:

• Jonathan Kennedy,
  President, Chief Executive Officer, Director
• B. Drew Davies,
  Chief Financial Officer, Executive Vice President
• Austin Noll,
  Executive Vice President and Chief Commercial Officer
• D. Christopher Chung,
  Vice President - Quality, Regulatory Affairs and Chief Medical Officer
• Benjamin Drew Davies,
  Exec. VP & CFO
• Austin F. Noll III,
  Exec. VP & Chief Commercial Officer
• Dr. D. Christopher Chung M.D.,
  VP of Quality, Regulatory Affairs & Chief Medical Officer
• Dr. D. Christopher Chung,
  VP of Quality, Regulatory Affairs & Chief Medical Officer
• Barbara Paul,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Lisa Heine,
  Independent Director
• Joshua Levine,
  Independent Director
• Thomas Joseph Sullivan,
  Pres, CEO & Director
• Alice Schroeder,
  Independent Director
• Thomas Sullivan,
  Independent Director
• Ilan Daskal,
  Independent Director
• William Hill,
  General Counsel
• Sean Langan,
  Vice President of Global Operations
• Lisa Paul,
  Vice President and Chief People Officer
• Douglas Balog,
  VP, Gen. Counsel & Sec.
• Lisa Paul,
  Chief People Officer & VP
• Ivan Pandiyan,
  VP of Global R&D
• Seán Langan,
  VP Global Operations
• Eric Guerin,
  Director
• Bryant M Moore,
  Director